Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10602585 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13695988 | 0.77 | ALDH1A1 (0.35) | ALDH1A1TSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13993901 | 0.76 | GAA (0.32) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3380115 | 0.76 | TSHR (0.38) | ALDH1A1TSHRCYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL10605965 | 0.74 | TSHR (0.36) | ALDH1A1TSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3982894 | 0.74 | CYP1A2 (0.31) | ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6050270 | 0.74 | CYP1A2 (0.31) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10869723 | 0.72 | OPRM1 (0.36) | ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL9514546 | 0.72 | KDM4E (0.30) | CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL9514899 | 0.72 | CYP1A2 (0.30) | CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4581012-A2 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024049979-A2 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SENDA BIOSCIENCES, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20130040914-A1 | PRODRUGS OF AN HIV REVERSE TRANSCRIPTASE INHIBITOR | MERCK SHARP & DOHME CORP. | 2013-02-14 | — | — | US | disclosed |
| US-20130040914-A1 | PRODRUGS OF AN HIV REVERSE TRANSCRIPTASE INHIBITOR | MERCK SHARP & DOHME CORP. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SGMS1, NPC1L1, SGMS2 | ALDH1A1 2239/4885TSHR 379/4885CYP1A2 4683/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | ALDH1A1 193/4885TSHR 1531/4885CYP1A2 4/4885 |
| US-20130040914-A1 | PRODRUGS OF AN HIV REVERSE TRANSCRIPTASE INHIBITOR | RNGTT, RPIA, REV1 | ALDH1A1 477/4885TSHR 3872/4885CYP1A2 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.